{
    "clinical_study": {
        "@rank": "26575", 
        "arm_group": [
            {
                "arm_group_label": "Olanzapine", 
                "description": "Olanzapine-treated patients with serious mental illness, such as schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder, psychosis NOS, delusional disorder or paranoid disorder."
            }, 
            {
                "arm_group_label": "Risperidone", 
                "description": "Risperidone-treated patients with serious mental illness, such as schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder, psychosis NOS, delusional disorder or paranoid disorder."
            }, 
            {
                "arm_group_label": "Iloperidone", 
                "description": "Iloperidone-treated patients with serious mental illness, such as schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder, psychosis NOS, delusional disorder or paranoid disorder."
            }
        ], 
        "biospec_descr": {
            "textblock": "Samples will be retained to test IL-6 and other inflammatory markers."
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "This study aims to utilize state of the art procedures such as the frequently sampled\n      intravenous glucose tolerance test (FSIVGTT), Bergman's Minimal Model Analysis, lipoprotein\n      analysis, and DEXA scans to demonstrate that a newer agent, iloperidone, is devoid of the\n      metabolic abnormalities associated with other atypical antipsychotic treatments, namely\n      olanzapine and risperidone, and offers an advantage over these other agents."
        }, 
        "brief_title": "Cross-Sectional Iloperidone IVGTT", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Schizophrenia", 
            "Serious Mental Illness", 
            "Metabolic Syndrome", 
            "Insulin Resistance", 
            "Glucose Metabolism"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Mental Disorders", 
                "Insulin Resistance", 
                "Schizophrenia", 
                "Metabolic Syndrome X"
            ]
        }, 
        "detailed_description": {
            "textblock": "This one-month research study examines how Fanapt\u00ae (iloperidone), Zyprexa\u00ae (olanzapine), or\n      Risperdal\u00ae (risperidone) affect glucose metabolism in patients with schizophrenia,\n      schizoaffective disorder, bipolar disorder, major depressive disorder, psychosis NOS,\n      delusional disorder or paranoid disorder. This study requires 3 research visits and includes\n      a physical exam, medical history, vitals, an EKG, cognitive testing, psychological rating\n      scales, a DEXA scan, a nutritional assessment, a 3-hour intravenous glucose tolerance test\n      (IVGTT) and a fasting blood draw."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male/Female ages 18-65 years\n\n          2. Capacity to provide informed consent\n\n          3. BMI between 20 and 30 kg/m\u00b2\n\n          4. Diagnosis of a serious mental illness, including schizophrenia, any subtype; or\n             schizoaffective disorder, any subtype; major depressive disorder, bipolar disorder,\n             psychosis NOS, delusional disorder and paranoid disorder\n\n          5. Treatment with iloperidone, risperidone, or olanzapine for at least 6 months\n\n          6. Stable dose of antipsychotic agent for at least one month\n\n          7. Well established compliance with out-patient medications and clinically stable\n\n          8. Female subjects will be eligible to participate in the study if they are of\n             non-childbearing potential or of child-bearing potential and willing to practice\n             appropriate birth control methods (complete abstinence from sexual intercourse,\n             female sterilization, sterilization of male partner, implants of levonorgestrel,\n             injectable progestogen, oral contraceptives, intrauterine devices, or double barrier\n             methods of contraception using spermicide with either a condom or diaphragm) during\n             the study.\n\n        Exclusion Criteria:\n\n          1. Inability to provide informed consent\n\n          2. Current substance abuse\n\n          3. Psychiatrically unstable and/or hospitalized in the past month\n\n          4. History of significant and untreated medical illness including severe cardiovascular,\n             hepatic, renal, or untreated thyroid disease; hepatitis; or HIV\n\n          5. Current insulin treatment for diabetes\n\n          6. Currently taking the following medications:  birth control pills containing\n             norgestrol, steroids, thiazide diuretics, or treatment with agents that induce weight\n             loss\n\n          7. Intentions of donating blood during or within 30 days of completion of the study.\n\n          8. Use of valproate or carbamazepine within four weeks of the study\n\n          9. History of immunosuppression\n\n         10. Current or recent radiation or chemotherapy treatment for cancer\n\n         11. Pregnancy or breastfeeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Subjects will include 60 outpatients between the ages of 18-65 with schizophrenia,\n        schizoaffective disorder, bipolar disorder, major depressive disorder, psychosis NOS,\n        delusional disorder or paranoid disorder. 60 subjects will be screened and 45 will enter\n        the cross-sectional study (15 olanzapine, 15 iloperidone, 15 risperidone-treated subjects\n        matched for BMI)."
            }
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01686815", 
            "org_study_id": "CILO522DUSXXT"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Risperidone", 
                "Olanzapine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "metabolic side effects", 
            "atypical antipsychotics", 
            "FSIVGTT"
        ], 
        "lastchanged_date": "March 26, 2014", 
        "location": {
            "contact": {
                "email": "lpetruzzi@partners.org", 
                "last_name": "Liana J Petruzzi, BA", 
                "phone": "617-912-7882"
            }, 
            "contact_backup": {
                "email": "lbriggs@partners.org", 
                "last_name": "Leah N Briggs, BS", 
                "phone": "617-912-7848"
            }, 
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02114"
                }, 
                "name": "Freedom Trail Clinic"
            }, 
            "investigator": {
                "last_name": "David C Henderson, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "3", 
        "official_title": "Cross-sectional Study to Compare Glucose and Lipid Metabolism in SMI Subjects Treated With Either Fanapt (Iloperidone), Zyprexa (Olanzapine), or Risperdal (Risperidone)", 
        "overall_contact": {
            "email": "lpetruzzi@partners.org", 
            "last_name": "Liana J Petruzzi", 
            "phone": "617-912-7882"
        }, 
        "overall_contact_backup": {
            "email": "lbriggs@partners.org", 
            "last_name": "Leah N Briggs, BS", 
            "phone": "617-912-7848"
        }, 
        "overall_official": {
            "affiliation": "Massachusetts General Hospital", 
            "last_name": "David C Henderson, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Difference between olanzapine- or risperidone-treated subjects, and Iloperidone-treated subjects on glucose metabolism as measured by the FSIVGTT procedure at one time point (Baseline).", 
                "measure": "Difference between cohorts in glucose metabolism", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }, 
            {
                "description": "Difference between olanzapine- or risperidone-subjects and subjects treated with iloperidone in triglyceride levels measured at one time point (Baseline).", 
                "measure": "Difference between cohorts in triglycerides", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }, 
            {
                "description": "Difference between olanzapine- or risperidone-subjects and subjects treated with iloperidone in LDL cholesterol levels measured at one time point (Baseline).", 
                "measure": "Difference between cohorts on LDL cholesterol", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01686815"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Massachusetts General Hospital", 
            "investigator_full_name": "David C. Henderson", 
            "investigator_title": "Associate Professor of Psychiatry", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "Massachusetts General Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "David C. Henderson", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Observational Model: Case Control, Time Perspective: Cross-Sectional", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}